Lilly's Retevmo Delivers Event-Free Survival Benefit As Adjuvant Therapy In Early-Stage Ret Fusion-Positive Lung Cancer
ReutersFeb 16, 2026 11:49 AM
Feb 16 (Reuters) - Eli Lilly and Co LLY.N:
LILLY'S RETEVMO (SELPERCATINIB) DELIVERS SUBSTANTIAL EVENT-FREE SURVIVAL BENEFIT AS AN ADJUVANT THERAPY IN EARLY-STAGE RET FUSION-POSITIVE LUNG CANCER
ELI LILLY - PHASE 3 LIBRETTO-432 STUDY MEETS PRIMARY ENDPOINT WITH IMPROVED EVENT-FREE SURVIVAL
ELI LILLY - OVERALL SURVIVAL RESULTS TRENDED IN FAVOR OF SELPERCATINIB, BUT WERE IMMATURE AT TIME OF THIS ANALYSIS WITH FEW EVENTS OBSERVED
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Should You Invest in the “Magnificent Seven” in 2026? One Stock or All of Them?
TradingKey - The Magnificent Seven defined markets in 2024 and remained at the heart of the 2025 story. Collectively, they have unparalleled control over AThe Magnificent Seven includes Nvidia (NVDA), Apple (AAPL), Alphabet (GOOG) (GOOGL), Microsoft (MSFT), Amazon (AMZN), Meta Platforms (META), andTradingKey
13 hours ago
Bitcoin Price Prediction 2029-2035: Institutional Accumulation and the U.S. Treasury’s Strategic Reserve Pivot
Explore the 2026 Bitcoin landscape: From the U.S. Strategic Reserve and Michael Saylor’s $75B war chest to Cathie Wood’s 2030 forecast. Is BTC the new Digital Gold?TradingKey
Fri, Feb 13
Is SaaS Dead? The Truth Behind the Software Meltdown, the Missing Floor, and the Peak That’s Not Coming Back
TradingKey - A trillion dollars just vanished from software stocks—this piece breaks down who AI is really killing, who quietly benefits, and why cheap SaaS may be the biggest value trap of this cycle.TradingKey
Thu, Feb 12
